Potential for Fundamental Change in the Treatment of Brain Cancer
Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer
Based on recent international research showing key role of the brain chemical, glutamate, in driving aggressive growth of GBM
Noxopharm owns what it believes to be world-leading technology in glutamate-inhibition
Major opportunity to slow GBM growth and help preserve normal brain function
Sydney, 18 October 2019: Noxopharm (ASX: NOX) announces that it will apply its glutamate- inhibition technology to the treatment of glioblastoma multiforme (GBM).
GBM remains a poorly managed cancer, with surgery, radiotherapy and the chemotherapy drug, temozolomide, the current standard of care, offering median survival of only 12-15 months.
For further information please download the attached PDF: